Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 1/20 | 0.47 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | DNM1L | O00429 | 2/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5724320 | 0.99 | OGA (0.46) | OGATYRDNM1LACKR3HSD11B1 | |
| SCHEMBL5724092 | 0.97 | OGA (0.44) | OGATYRDNM1LACKR3HSD11B1 | |
| SCHEMBL5723946 | 0.95 | ACKR3 (0.43) | OGATYRDNM1LACKR3HSD11B1 | |
| SCHEMBL5723964 | 0.84 | OGA (0.46) | OGA | |
| SCHEMBL5724259 | 0.84 | OGA (0.41) | OGAACKR3NPC1RAB9A | |
| SCHEMBL5724054 | 0.84 | TYR (0.51) | OGATYRDNM1LACKR3HSD11B1 | |
| SCHEMBL5724459 | 0.83 | OGA (0.49) | OGATYRDNM1LACKR3HSD11B1 | |
| SCHEMBL5723880 | 0.81 | PARP1 (0.39) | OGAACKR3 | |
| SCHEMBL5724061 | 0.81 | OGA (0.47) | OGATYRDNM1LACKR3HSD11B1 | |
| SCHEMBL5723657 | 0.79 | HRH3 (0.47) | OGAALDH1A1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1340757-B1 | 1-METHYLCARBAPENEM DERIVATIVES | SANKYO CO (JP) | 2006-10-11 | — | — | EP | disclosed |
| US-7001897-B2 | 1-methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-02-21 | — | — | US | disclosed |
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-22 | — | — | US | disclosed |
| EP-1340757-A1 | 1-METHYLCARBAPENEM DERIVATIVES | Sankyo Company, Limited (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | CD14, CPT1A, ACMSD | OGA 3469/4885TYR 2189/4885DNM1L 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.